News
KYNB
6.88
+2.69%
0.18
Weekly Report: what happened at KYNB last week (0615-0619)?
Weekly Report · 1d ago
Kyntra Bio Shareholders Back Board, Pay and Auditor
TipRanks · 06/16 10:44
Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting
PUBT · 06/16 10:02
Weekly Report: what happened at KYNB last week (0608-0612)?
Weekly Report · 06/15 09:16
Kyntra Reports Phase 3 MATTERHORN Data For Roxadustat In LR-MDS; U.S. Phase 3 Planned In H2 2026
NASDAQ · 06/12 15:01
Kyntra Bio to present additional MATTERHORN trial data at EHA
TipRanks · 06/11 20:20
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients
Benzinga · 06/11 20:07
KYNTRA BIO PRESENTS NEW ROXADUSTAT DATA ON IMPROVEMENTS IN TRANSFUSION INDEPENDENCE REGARDLESS OF RING SIDEROBLAST STATUS IN PATIENTS WITH ANEMIA DUE TO LOWER-RISK MYELODYSPLASTIC SYNDROMES
Reuters · 06/11 20:05
KYNTRA BIO - ROXADUSTAT SHOWS NO NEW SAFETY SIGNALS IN LR-MDS PATIENTS
Reuters · 06/11 20:05
Kyntra Bio says Phase 3 MATTERHORN post-hoc analysis shows roxadustat lifts transfusion independence in lower-risk MDS
PUBT · 06/11 20:05
Kyntra Bio Receives Final Payment for China Divestiture
TipRanks · 06/09 22:25
Kyntra Bio Price Target Announced at $30.00/Share by Rodman & Renshaw
Dow Jones · 06/09 12:01
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30
Benzinga · 06/09 11:50
Kyntra Bio initiated with a Buy at Rodman & Renshaw
TipRanks · 06/09 11:16
Weekly Report: what happened at KYNB last week (0601-0605)?
Weekly Report · 06/08 09:15
Weekly Report: what happened at KYNB last week (0525-0529)?
Weekly Report · 06/01 09:17
Fluidra appoints Juan Graham CFO, succeeding Xavier Tintoré
PUBT · 05/28 06:37
Weekly Report: what happened at KYNB last week (0518-0522)?
Weekly Report · 05/25 09:17
Kyntra Bio Rocked by CEO’s Sudden Insider Stock Sale
TipRanks · 05/19 02:17
Kyntra Bio CEO Thane Wettig buys 2,800 shares worth $19,852
PUBT · 05/18 12:00
More
Webull provides a variety of real-time KYNB stock news. You can receive the latest news about KYNTRA BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.